Loading organizations...
Edgewise Therapeutics develops novel oral therapies for serious skeletal and cardiac muscle disorders. Its lead product, EDG-5506 (sevasemten), is a small molecule designed to selectively modulate fast muscle fiber contraction. This precision limits injurious hypercontraction stress and muscle damage from dystrophin absence, protecting muscle tissue in conditions like Duchenne and Becker muscular dystrophy.
The company was co-founded in 2017 by Badreddin Edris, Ph.D., Kevin Koch, Ph.D., Alan Russell, Ph.D., and Peter Thompson, M.D. This team brought extensive expertise in muscle biology and drug development, leveraging insights to address unmet needs in muscle disease treatment. Dr. Russell serves as Chief Scientific Officer and Dr. Koch as President and CEO.
Edgewise Therapeutics targets patients with debilitating muscle diseases, primarily muscular dystrophies. Its mission delivers transformative treatments that protect muscle health and function, improving functional capacity and quality of life for affected individuals. The company envisions leading the field of muscle-focused therapeutics.
Edgewise Therapeutics has raised $145.0M across 2 funding rounds.
Edgewise Therapeutics has raised $145.0M in total across 2 funding rounds.
Edgewise Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing novel therapeutics for serious muscle diseases.[1][2] The premise of your query contains an inaccuracy that should be clarified before proceeding with the requested analysis.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics for patients suffering from serious muscle diseases, including muscular dystrophies and cardiac conditions.[2][3] The company's mission is to develop transformative treatments for muscular dystrophies by leveraging its proprietary platform focused on small molecule therapeutics and targeted protein degradation.[1][3]
The company serves patients with life-limiting muscle disorders who currently lack effective treatment options. Its primary focus areas include Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), myotonic dystrophy type 1 (DM1), hypertrophic cardiomyopathy, and heart failure.[2][3][6] Edgewise's lead program, EDG-5506, is currently in clinical trials for DM1and has demonstrated promising early-stage results.[3] The company is also advancing sevasemten, an orally administered first-in-class fast skeletal myosin inhibitor for muscular dystrophies.[6]
Edgewise Therapeutics was founded in 2017 and has rapidly emerged as a leader in targeted protein degradation and muscle-focused therapeutics.[3] The company established its headquarters in Boulder, Colorado, deliberately choosing the location to foster creative thinking and capitalize on the region's scientific talent and nearby research institutions.[4] This founding decision reflects the company's commitment to building a unique culture centered on muscle biology and patient-centric drug development.
Edgewise operates within the rare disease and muscle-focused therapeutics sector, addressing a significant gap in treatment options for debilitating neuromuscular and skeletal disorders.[3] The company is positioned at the forefront of innovative drug discovery, leveraging advances in understanding muscle biology and protein degradation mechanisms. The timing is particularly relevant as the biotech industry increasingly recognizes the potential of organ-specific therapeutic approaches, and Edgewise's singular focus on muscle diseases allows it to develop deep expertise in a traditionally underserved area.
The company's commitment to advancing scientific understanding of muscle biology contributes to the broader ecosystem by collaborating with patient communities, researchers, and healthcare providers to accelerate drug development.[1] This collaborative approach influences how other biotech firms approach rare disease development.
Edgewise Therapeutics is advancing a robust pipeline of molecules targeting multiple muscular indications, with its next earnings announcement scheduled for February 19, 2026.[3] The company's future trajectory will depend on clinical trial outcomes for its lead programs, particularly EDG-5506 in DM1 and sevasemten in muscular dystrophies. As the company progresses through clinical development, its ability to demonstrate efficacy and safety in these rare, serious conditions will determine its impact on the treatment landscape for muscle diseases. The broader trend of precision medicine and organ-specific therapeutic approaches positions Edgewise favorably within the biotech ecosystem, particularly as patient advocacy and unmet medical need continue to drive investment in rare disease therapeutics.
Edgewise Therapeutics has raised $145.0M in total across 2 funding rounds.
Edgewise Therapeutics's investors include Viking Global Investors, 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group, U.S. Venture Partners, Cormorant Asset Management, CureDuchenne Ventures, Deerfield Management.
Edgewise Therapeutics has raised $145.0M across 2 funding rounds. Most recently, it raised $95.0M Series C in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $95.0M Series C | Viking Global Investors | 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group, U.S. Venture Partners, Cormorant Asset Management, CureDuchenne Ventures, Deerfield Management, Janus Henderson Investors, Logos Capital, New Leaf Ventures, Novo Holdings, RA Capital Management, Surveyor Capital, Wellington Management |
| Sep 1, 2019 | $50.0M Series B | U.S. Venture Partners, Ken Harrison | 5AM Ventures, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, The Column Group, Debra Miller, Robert Jackson, New Leaf Venture Partners |